Unité des Virus Émergents (UVE: Aix-Marseille University-IRD 190-Inserm 1207), Marseille, France.
Sci Rep. 2022 Mar 18;12(1):4683. doi: 10.1038/s41598-022-08559-5.
The emergence and rapid spread of the Omicron variant of SARS-CoV-2, which has more than 30 substitutions in the spike glycoprotein, compromises the efficacy of currently available vaccines and therapeutic antibodies. Using a clinical strain of the Omicron variant, we analyzed the neutralizing power of eight currently used monoclonal antibodies compared to the ancestral B.1 BavPat1 D614G strain. We observed that six of these antibodies have lost their ability to neutralize the Omicron variant. Of the antibodies still having neutralizing activity, Sotrovimab/Vir-7831 shows the smallest reduction in activity, with a factor change of 3.1. Cilgavimab/AZD1061 alone shows a reduction in efficacy of 15.8, resulting in a significant loss of activity for the Evusheld cocktail (42.6-fold reduction) in which the other antibody, Tixagevimab, does not retain significant activity against Omicron. Our results suggest that the clinical efficacy of the initially proposed doses should be rapidly evaluated and the possible need to modify doses or propose combination therapies should be considered.
SARS-CoV-2 的奥密克戎变异株的出现和快速传播，其刺突糖蛋白有超过 30 处突变，使目前可用的疫苗和治疗性抗体的功效受到影响。我们使用奥密克戎变异株的临床分离株，分析了与原始 B.1 BavPat1 D614G 株相比，目前使用的八种单克隆抗体的中和能力。我们观察到其中六种抗体已丧失中和奥密克戎变异株的能力。在仍具有中和活性的抗体中，Sotrovimab/Vir-7831 的活性降低幅度最小，活性变化倍数为 3.1。Cilgavimab/AZD1061 的疗效降低 15.8，导致 Evusheld 鸡尾酒（活性降低 42.6 倍）的疗效显著丧失，其中另一种抗体 Tixagevimab 对奥密克戎没有保留显著的活性。我们的结果表明，应迅速评估最初建议剂量的临床疗效，并考虑可能需要修改剂量或提出联合治疗方案。
